Denise Myshko is a journalist at AJMC - The American Journal of Managed Care. She covers a wide range of topics within the healthcare sector, including pharmaceuticals, healthcare technology, and patient care, with a particular focus on medical specialties such as dermatology and immunotherapy. Denise's work has been featured in prominent publications including Drug Topics, Medical Economics, and Managed Healthcare Executive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Denise Myshko focuses on the healthcare and pharmaceutical industry, with a particular emphasis on drug pricing, clinical trials, and gene therapies. She frequently references data in her coverage, indicating a preference for fact-based analysis.
Given this focus, Denise is likely to be interested in pitches that offer insights into the latest developments in the pharmaceutical industry or provide expert commentary on issues related to drug pricing, clinical trials, and gene therapies. Sources who can provide data-driven analysis or insider perspectives would likely resonate well with her reporting style.
While she doesn't have a specific geographic focus mentioned, it's important to note that Denise may cover international as well as domestic news items within the healthcare and pharmaceutical space.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Wehrwein, Denise Myshko
Industry leaders Tom Kraus and Shawn Gremminger debated 340B's value during a Managed Healthcare Executive/Drug Topics webinar. Panelists clashed over transparency, safety-net eligibility, and how 340B savings should be spent.
By: Denise Myshko
Once-weekly zabopegdutide produced weight loss, better glycemic control, and favorable liver enzyme changes in a 67-patient phase 2 trial of patients with MASH.
By: Denise Myshko
The approval of centanafadine, now with the brand name, Simtriyo, introduces a new treatment approach for adults and children with ADHD.
By: Denise Myshko
In the VOGUE trial, Dovato matched Biktarvy at week 48, demonstrating that it was noninferior in HIV-1 viral suppression in treatment-naïve adults, including high-risk patients.
By: Denise Myshko
Data presented at the International AIDS Conference 2026 show Cabenuva reduced viral rebound in adolescents versus oral therapy, but access to long-acting injectables remains limited where need is greatest, investigators said.
By: Denise Myshko
Specialty drug spend is being driven by utilization, while the non-specialty trend is being pushed up as a result of the use of GLP-1s for diabetes and for weight loss.
By: Denise Myshko
Children using virtual reality needed significantly lower nitrous oxide concentrations during Botox procedures, potentially reducing side effects like nausea, vomiting, and hallucinations, researchers reported.
By: Denise Myshko
Like Journavx, LTG-001 is a Nav1.8 inhibitor that is designed to selectively block the transmission of pain without the risk of addiction.
From her perch at Navitus, Crosson has become a prominent advocate on PBM transparency and prescription drug affordability issues, frequently speaking with policymakers, industry groups, and healthcare stakeholders about legislative reforms and regulatory trends.
